NCT02962531View on ClinicalTrials.gov

Relative Bioavailability Study of IX-01 Caplet Versus Aqueous Dispersion and Food Effect of the Caplet in Healthy Males

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Healthy
Interventions
DRUG

IX-01 caplets 1600 mg (4 x 400 mg), fasted

oral dose under fasted conditions

DRUG

IX-01 caplets 1600 mg (4 x 400 mg), fed

oral dose under fed conditions

DRUG

IX-01 aqueous dispersion 1600 mg (20 mL), fasted

oral dose under fasted conditions

Trial Locations (1)

78217

Worldwide Clinical Trials Early Phase Services, LLC, San Antonio

All Listed Sponsors
lead

Ixchelsis Limited

INDUSTRY

NCT02962531 - Relative Bioavailability Study of IX-01 Caplet Versus Aqueous Dispersion and Food Effect of the Caplet in Healthy Males | Biotech Hunter | Biotech Hunter